$15.82
3.74% today
Nasdaq, Aug 12, 09:15 pm CET
ISIN
US00773J1034
Symbol
SYRE

Aeglea BioTherapeutics Inc Stock price

$15.25
-0.44 2.80% 1M
-6.90 31.15% 6M
-8.03 34.49% YTD
-9.06 37.27% 1Y
+2.75 22.02% 3Y
-147.50 90.63% 5Y
-229.00 93.76% 10Y
-229.00 93.76% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
+0.09 0.59%
ISIN
US00773J1034
Symbol
SYRE
Industry

Key metrics

Basic
Market capitalization
$921.1m
Enterprise Value
$394.5m
Net debt
positive
Cash
$526.6m
Shares outstanding
60.4m
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
2.0
Financial Health
Equity Ratio
85.1%
Return on Equity
-40.2%
ROCE
-
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
- | $0.0
EBITDA
- | $-223.6m
EBIT
- | $-233.1m
Net Income
- | $-186.9m
Free Cash Flow
$-154.2m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -7.2%
EBIT
- | -11.7%
Net Income
- | 10.2%
Free Cash Flow
1.4%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
-
FCF per Share
$-2.6
Short interest
28.9%
Employees
65
Rev per Employee
$0.0
Show more

Is Aeglea BioTherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Aeglea BioTherapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Aeglea BioTherapeutics Inc forecast:

16x Buy
89%
2x Hold
11%

Analyst Opinions

18 Analysts have issued a Aeglea BioTherapeutics Inc forecast:

Buy
89%
Hold
11%

Financial data from Aeglea BioTherapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 46 46
30% 30%
-
- Research and Development Expense 163 163
24% 24%
-
-209 -209
16% 16%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -209 -209
16% 16%
-
Net Profit -208 -208
39% 39%
-

In millions USD.

Don't miss a Thing! We will send you all news about Aeglea BioTherapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aeglea BioTherapeutics Inc Stock News

Neutral
The Motley Fool
6 days ago
Spyre (SYRE) Q2 R&D Up 23% Loss Narrows
Neutral
GlobeNewsWire
7 days ago
Reported positive interim Phase 1 results for two next-generation TL1A antibodies, demonstrating both were well-tolerated, exhibited pharmacokinetic ("PK") profiles supporting quarterly or biannual dosing, and full TL1A engagement through up to 20 weeks of follow-up
Neutral
GlobeNewsWire
11 days ago
WALTHAM, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's indep...
More Aeglea BioTherapeutics Inc News

Company Profile

Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.

Head office United States
CEO Cameron Turtle
Employees 65
Founded 2013
Website spyre.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today